Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Est disponible Mounjaro en Espaa
Lowers blood glucose Stimulates insulin secretion in a glucose-dependent manner Suppresses glucagon secretion Delays gastric emptying Induces weight loss Reduces appetite and food intake via central pathways Enhances satiety Cardiovascular protection Reduces major adverse cardiovascular events in high-risk patients Approved Indications Type 2 diabetes mellitus Improves glycemic control in adults Reduces cardiovascular risk in patients with established cardiovascular disease Chronic weight management Adults with obesity (BMI 30 kg/m) Adults with overweight (BMI 27 kg/m) and at least one weight-related comorbidity Oral formulation Glycemic control in adults with type 2 diabetes Dosage and Administration (Injectable) Starting dose : 0.25 mg once weekly for 4 weeks Maintenance dose : 0.5 mg once weekly Maximum dose : 1 mg once weekly Injection sites : Abdomen, thigh, or upper arm Common Adverse Reactions Gastrointestinal : Nausea, vomiting, diarrhea, constipation, abdominal distension Hypoglycemia (low risk as monotherapy) Headache, fatigue, injection-site reaction All products are produced exclusively for controlled laboratory research and development applications.Not for human or animal consumption.
Our firm continues to monitor safety concerns involving GLP-1 RA drugs, including vision loss
Once alcohol enters your bloodstream, only time and liver metabolism can reduce BAC levels
